UNSPSC 51142565: Pramipexole dihydrochloride monohydrate

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C10H17N3S.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3D867NP06J, chemically known as 2,6-benzothiazolediamine, 4,5,6,7-tetrahydro-n6-propyl-, dihydrochloride, (s)- but more generally known as pramipexole dihydrochloride, which bears US NIH Compound Identifier 119569. European Medicines Agency schedules Pramipexole dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04004MIG.

Most nations, for tariff and trade purposes, schedule pramipexole dihydrochloride monohydrate under HS 29341000. SMILES: CCCN[C@H]1CCC2C(SC(N2)N)C1.O.CL.CL.

UNSPSC 51142565 Pramipexole dihydrochloride monohydrate is a Commodity code that captures pharmaceutical products state and local health agencies procure for community health initiatives, emergency response, and pharmacy benefit programs. Recent state and local solicitations under this code show activity spanning naloxone procurement for overdose response, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals distributed through cooperative purchasing arrangements. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving participating state agencies and local government facilities. Procurement vehicles range from individual county competitive bidding processes to statewide cooperative agreements with administrative oversight and multi-jurisdictional participation.

Geographic activity centers on Florida and Minnesota, with Texas HHS involvement in exploratory procurement phases. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, with a response deadline of July 26, 2026; the procurement includes a two-year initial term with optional one-year renewal and requires E-Verify compliance and specific insurance coverage. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026; evaluation prioritized price competitiveness at seventy-five percent and required vendors to maintain relationships with at least two of three authorized wholesalers. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather preliminary market intelligence on direct-to-manufacturer prescription programs for a future Therapeutic Pharmacy Initiative, representing early-stage procurement planning rather than immediate competitive opportunity.